[Effects of 3-hydroxypyridine and succinic acid derivates on the dynamics of vertebral/neurologic symptoms after the surgical treatment of disk herniations]

Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(3):19-24.
[Article in Russian]

Abstract

A study of 3-hydroxypiridine and succinic acid derivates (emoxipin, reamberin and mexidol) effects on the 14 week dynamics of vertebral/neurologic symptoms was performed in 136 patients after the surgical treatment of disk herniations. Data obtained demonstrated the reduction of severity of neurodystrophic and radicular syndromes without significant changes in dorsalgia, psychological maladaptation (PM) and disability scores (DS) during 3.5 months in patients treated with emoxipin (150 mg i.v., daily) for two weeks after the microdiscectomy. The two-week administration of reamberin (400 mg i.v., daily) led to the early attenuation of neuropathic pain. The reduction of sings of radicular compression and DS measured with the Roland-Morris questionnaire were delayed for 3 months. Mexidol (300 mg i.v., once a day during two weeks) demonstrated the highest efficacy. This drug attenuated radicular and neurodystrophic syndromes, nociceptive and neuropathic pain, reduced PM and DS measured with both the Roland-Morris and the Oswestry questionnaires during 14 weeks after the surgery.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Female
  • Humans
  • Intervertebral Disc Displacement / drug therapy*
  • Intervertebral Disc Displacement / physiopathology*
  • Intervertebral Disc Displacement / surgery
  • Male
  • Meglumine / analogs & derivatives*
  • Meglumine / therapeutic use
  • Middle Aged
  • Neuralgia / drug therapy
  • Neuralgia / physiopathology
  • Picolines / therapeutic use*
  • Postoperative Period
  • Pyridines / therapeutic use*
  • Spine / drug effects
  • Spine / physiopathology
  • Succinates / therapeutic use*

Substances

  • Picolines
  • Pyridines
  • Reamberin
  • Succinates
  • emoxypine succinate
  • 3-hydroxypyridine
  • Meglumine
  • 6-methyl-2-ethyl-3-hydroxypyridine